Skip to main content
. Author manuscript; available in PMC: 2015 Jun 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2014 Mar 27;34(6):1307–1313. doi: 10.1161/ATVBAHA.114.303252

Figure 1. Association of the FMO locus with FMO3 mRNA levels, plasma TMAO levels, and risk of CAD in humans.

Figure 1

Using a publicly available eQTL liver dataset, 57 SNPs were tested for association with hepatic FMO3 mRNA levels, one of which (rs2075988) yielded a significant p-value (4.5×10−4) after Bonferroni correction for multiple testing (A). In the GeneBank cohort, none of the 471 SNPs tested in the FMO locus yielded significant association with plasma TMAO levels (B). Evaluation of the FMO locus with risk of CAD using 388 SNPs available from the results of the CARDIoGRAM consortium did not reveal any significant associations (C). The same genomic interval spanning ~451kb across the FMO cluster on chromosome 1q24.3 is shown for all three plots and the variant most strongly associated with FMO3 mRNA levels is given as the reference SNP (rs2075988).